MDS Diagnostic Services Selects bioMerieux to Fully Automate Eight Labs
24 Maggio 2005 - 3:02PM
PR Newswire (US)
MDS Diagnostic Services Selects bioMerieux to Fully Automate Eight
Labs MDS Diagnostic Services, the largest provider of laboratory
testing services in Canada, to implement the VITEK(R) 2 DURHAM,
N.C., May 24 /PRNewswire/ -- bioMerieux, Inc., a leading medical
diagnostics company, today announced it has secured a five-year
contract with MDS Diagnostic Services, the largest provider of
laboratory testing services in Canada. Under the terms of this
arrangement, bioMerieux will supply its VITEK(R) 2 automated
bacteriology identification and susceptibility testing (ID/AST)
system to eight MDS laboratories in British Columbia and Ontario,
Canada. "We serve patients directly through our own community
medical laboratories and the hospital labs we manage, which
combined, provide more than 50 million clinical tests every year,"
said Dr. Brian Sheridan, senior vice president of medical affairs,
MDS Diagnostic Services. "After evaluating several providers, we
selected the VITEK 2 because of its ability to manage, with
accuracy and speed, the large volumes of diagnostic tests processed
for physicians and patients in our labs every day." VITEK 2
provides rapid results processing (a two to six hour average
turnaround), which enables MDS Diagnostic Services to provide
timely and accurate test results to the more than 21,000 health
care providers and 17 million patients it serves annually. "We were
willing to invest in a fully automated system to support our goal
of delivering the highest quality service to our customers,"
Sheridan continued. "Our dedication to research and development
continues to broaden the realm of in vitro diagnostics," said Eric
Bouvier, president and CEO, bioMerieux, Inc., North America. "We
are proud to be selected by MDS Diagnostic Services and look
forward to developing this new relationship and providing MDS with
innovative, proven and cost-efficient products, such as the VITEK
2." The VITEK 2 is a fully automated bacterial identification and
antibiotic susceptibility testing system. The system also includes
a highly advanced software system that then interprets the
identified bacteria's antibiotic resistance patterns. Additionally,
bioMerieux has designed a unique, 64-well susceptibility card
specifically for MDS to further enhance productivity on their VITEK
2 instruments. The VITEK 2 offers random or batch processing, rapid
results and a quality control module. The system is used for
bacterial and yeast identification, antimicrobial susceptibility
testing and urine screening and features an Advanced Expert(TM)
System (AES) and Observa(R), complete data management system. The
VITEK 2 has already been implemented in two labs in British
Columbia. Implementation of VITEK 2 in MDS' Ontario labs will begin
this summer. About MDS Diagnostic Services MDS Diagnostic Services,
a business unit of MDS Inc. (TSX: MDS) (NYSE:MDZ), is a leading
provider of laboratory testing and management services. MDS Inc.
has more than 9,000 highly skilled people in 25 countries. MDS Inc.
provides a diverse range of superior products and services to
increase its customers' speed, precision and productivity in the
drug development and disease diagnosis processes. MDS Inc. is a
global, values- driven health and life sciences company, recognized
for our reliability and collaborative relationships as we help
create better outcomes in the treatment of disease. Find out more
at http://www.mdsintl.com/ or by calling 1-888-MDS-7222, 24 hours a
day. About bioMerieux, Inc. bioMerieux, Inc. is the U.S. subsidiary
of bioMerieux S.A., a company headquartered in France. bioMerieux
is a leading international diagnostics group that specializes in
the field of in vitro diagnostics for clinical and industrial
applications. bioMerieux designs, develops, manufactures and
markets systems (i.e. reagents, instruments and software) used in:
- Clinical applications: the diagnosis of infectious diseases such
as hepatitis, HIV, tuberculosis and respiratory illnesses, as well
as pathologies such as certain cardiovascular diseases and certain
cancers, based on the analysis of biological samples (such as
blood, saliva or urine); and - Industrial applications: the
microbiological analysis of food, environments (such as water and
air), surfaces and pharmaceutical and cosmetic products, based on
product or environmental samples. In 2004, bioMerieux sales reached
931 million euros (i.e., approximately 1.2 billion dollars). The
company is present in more than 130 countries through 33
subsidiaries and a large network of distributors, which positions
the company well to benefit from the growth potential of the in
vitro diagnostics market. Some important drivers that underpin this
growth are aging populations and age-related illness, illnesses
related to life-style and eating habits, emerging new pathogens,
the development of antibiotic-resistant bacteria, the fight against
bio-terrorism, and the recognition of the importance of the quality
of food products. bioMerieux is listed on the Eurolist by Euronext
Paris (symbol "BIM", ISIN code: FR0010096479). For more
information, visit the web site at http://www.biomerieux-usa.com/ .
DATASOURCE: bioMerieux CONTACT: Paige Sargent of
French-West-Vaughan, +1-919-277-1162, or ; or Christelle Chabert,
+33 (0)4 78 87 52 01, or , or Investor Relations, Dominique
Takizawa or Herve Laurent, +33 (0)4 78 87 22 37, or all of
bioMerieux Web site: http://www.biomerieux-usa.com/
http://www.mdsintl.com/
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024